May, 2017

Biotech Industry Wary of Proposed Changes to R&D Tax Incentive

May 2nd, 2017

The Australian biotech industry has concerns about an overhaul of the R&D tax incentive scheme, which could involve eligibility restrictions and cuts. The government has proposed capping R&D tax refunds at $2 million, which could be realised in this month’s federal budget. The uncertainty has already impacted the sector, with both Australian and international companies reconsidering doing clinical trials here. As Chris Nave, managing director of Brandon Capital Partners commented, “$2 million isn’t worth the cost of setting up an […]

Read More

Major Challenges for Australian Innovation

May 1st, 2017

Innovation is as important as ever, especially for traditional industries. While Australia already has world-class sectors and companies, it is necessary for us to encourage the next generation of great companies. In 2015, Australia was labelled a ‘stall out’ country by Harvard Business Review, meaning a country that evolved quickly in the past but has now stalled and is slowly receding. We have fallen behind other nations in areas like data analysis. To address this, Bill Ferris, Chair of Innovation and […]

Read More

Email this job

[recaptcha]